For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Anti-peptic Ulcre drug is one of various classes of drugs with different action mechanisms used to treat or ameliorate peptic ulcer or irritation of the gastrointestinal tract.
Scope of the Report:
China's anti-trust crackdown on foreign pharmaceutical companies has left many foreign investors in the healthcare industry shocked. The Chinese government has had no qualms about openly stating that it prefers hospitals to purchase from domestic producers. That said, China's homegrown manufacturers of medical devices and medicine still lack the sophistication to produce many of the more advanced health care products the country needs. Amid rising living standards and an aging population, China's healthcare needs are set to rise sharply in the coming years.
In April 2015, China amended its Drug Administration Law, introducing two major changes.
The first is a simplification of the company set-up procedure for pharmaceutical companies. Prior to the amendment, investors that wanted to manufacture or distribute pharmaceuticals needed to have a Drug Manufacturing License or a Drug Distribution License before applying for a business license. Now, investors may apply for these after the company has been set up, significantly speeding up the incorporation process.
More importantly, the amendment removes the price controls that the Chinese government had in place for medicines. As of the year 2000, medicines that were listed on the government's Medical Insurance Catalog, and those medicines on which there was a monopoly, had their prices fixed or guided by the government. About 23 percent of the medicines on the Chinese market had government fixed or guided prices. The price of other medicines was left to market forces. While these price restrictions are now fully removed, companies still need to abide by China's anti-trust laws. Companies abusing their dominant market position are still punishable under Chinese law.
While recent moves have made it easier for foreign investors to introduce new medical products to the Chinese market, the Chinese government has at the same time placed restraints on advertising healthcare products. The final text of the revised Advertising Law was released by the National People's Congress, China main legislative body, in late April 2015. The law comes into force in September 2015.
The 2015 Advertising Law has special stipulations about advertising for medicine and medical devices. For one, advertising for anesthetics, psychotropic drugs, toxic and radioactive drugs for medical use is not allowed, nor is advertisement for drugs, treatment plans and medical devices to combat drug addiction. Advertising for prescription drugs other than those mentioned previously is only allowed in professional medical journals.
The content for medical advertisements is regulated as well. Any advertisement for drugs, medical treatment or medical devices may not contain the following:
The worldwide market for Anti-Peptic Ulcer Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2024, from xx million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Anti-Peptic Ulcer Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- AstraZeneca
- Ask-pharm
- Takeda
- Yangtze River Pharm
- Shandong Luoxin
- Huadong Medicine
- Changzhou Siyao
- Beijing Yuekang
- Guangdong Dahua
- Xian Janssen
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Proton Pump Inhibitors (PPIs)
- Potassium-Competitive Acid Blockers (P-CAB)
- Antacids
- H2 Antagonists
- Ulcer Protective Drugs
Market Segment by Applications, can be divided into
- Gastritis
- Gastric Ulcers
- Duodenal Ulcers
- Gastroesophageal Reflux Disease (GERD)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Anti-Peptic Ulcer Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Anti-Peptic Ulcer Drugs, with price, sales, revenue and global market share of Anti-Peptic Ulcer Drugs in 2017 and 2018.
Chapter 3, the Anti-Peptic Ulcer Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Anti-Peptic Ulcer Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Anti-Peptic Ulcer Drugs market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Anti-Peptic Ulcer Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.